G&A at other companies
Segments
By segment
See fullOther financials
Where this comes from
Reported directly by Vaxcyte, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vaxcyte, Inc.'s g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vaxcyte, Inc.'s G&A?
- Vaxcyte, Inc. (PCVX) reported G&A of $33.07M in Q1 2026.
- How has Vaxcyte, Inc.'s G&A changed year-over-year?
- Vaxcyte, Inc.'s G&A increased by 1.3% year-over-year, from $32.66M to $33.07M.
- What is the long-term trend for Vaxcyte, Inc.'s G&A?
- Over 4 years (2021 to 2025), Vaxcyte, Inc.'s G&A has grown at a 50.4% compound annual growth rate (CAGR), from $25.26M to $129.37M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.